Schnieders Capital Management LLC Lowers Stake in Pfizer Inc. $PFE

Key Points

• Schnieders Capital Management LLC reduced its holdings in Pfizer Inc. by 60.1%, resulting in ownership of 23,857 shares valued at approximately $578,000 at the end of the second quarter.
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding expectations of $0.58, with revenues of $14.65 billion, showcasing a 10.3% increase year-over-year.
• Pfizer announced a quarterly dividend of $0.43 per share, set to be paid on December 1st, which represents a 7.0% dividend yield.

Schnieders Capital Management LLC lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 60.1% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 23,857 shares of the biopharmaceutical company's stock after selling 35,949 shares during the period. Schnieders Capital Management LLC's holdings in Pfizer were worth $578,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. purchased a new position in Pfizer during the 1st quarter valued at about $27,000. Bayforest Capital Ltd purchased a new position in shares of Pfizer in the first quarter valued at approximately $28,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter valued at approximately $28,000. Harbor Asset Planning Inc. purchased a new stake in Pfizer during the 2nd quarter worth approximately $29,000. Finally, WPG Advisers LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $35,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.2%

PFE opened at $24.52 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.36. The company has a market cap of $139.38 billion, a P/E ratio of 13.04, a PEG ratio of 0.81 and a beta of 0.55. The business's 50-day simple moving average is $24.89 and its 200-day simple moving average is $24.11.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm's revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on PFE shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a research report on Wednesday, October 8th. UBS Group restated a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup lifted their price objective on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Morgan Stanley cut their target price on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research note on Friday, October 10th. Finally, Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.